Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy for pancreatic cancer.
Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, Neoptolemos JP. Springfeld C, et al. Among authors: jager d. Presse Med. 2019 Mar;48(3 Pt 2):e159-e174. doi: 10.1016/j.lpm.2019.02.025. Epub 2019 Mar 15. Presse Med. 2019. PMID: 30879894 Review.
[Adjuvant treatment of pancreatic cancer].
Michalski CW, Kleeff J, Jäger D, Friess H, Büchler MW. Michalski CW, et al. Among authors: jager d. Dtsch Med Wochenschr. 2007 Apr 13;132(15):803-7. doi: 10.1055/s-2007-973624. Dtsch Med Wochenschr. 2007. PMID: 17427090 Review. German. No abstract available.
A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
Märten A, Schmidt J, Ose J, Harig S, Abel U, Münter MW, Jäger D, Friess H, Mayerle J, Adler G, Seufferlein T, Gress T, Schmid R, Büchler MW. Märten A, et al. Among authors: jager d. BMC Cancer. 2009 May 26;9:160. doi: 10.1186/1471-2407-9-160. BMC Cancer. 2009. PMID: 19470159 Free PMC article. Clinical Trial.
An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinical benefit - PANUSCO.
Märten A, Wente MN, Ose J, Büchler MW, Rötzer I, Decker-Baumann C, Karapanagiotou-Schenkel I, Harig S, Schmidt J, Jäger D. Märten A, et al. Among authors: jager d. BMC Cancer. 2009 Nov 27;9:412. doi: 10.1186/1471-2407-9-412. BMC Cancer. 2009. PMID: 19943918 Free PMC article. Clinical Trial.
561 results